ImmunoMet Therapeutics
PrivateLast Round
Series C
Oct 19, 2022
Total Funding Raised
$41.8M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
ImmunoMet Therapeutics is a clinical-stage biotechnology company developing novel anti-cancer and anti-fibrotic therapies by targeting cellular metabolism.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ImmunoMet Therapeutics Comparables
Compare ImmunoMet Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Dracen Pharmaceuticals, Inc. | 77% | |
| Cornerstone Pharmaceuticals, Inc. | 75% | |
| One-carbon Therapeutics AB | 73% |
ImmunoMet Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Oct 19, 2022 | ||||
| Series B Extension | Dec 31, 2021 | ||||
| VC Round | Feb 8, 2021 | ||||
| Series B Extension | Feb 5, 2020 | ||||
| Convertible Debt | May 16, 2018 | ||||
Series B | Mar 7, 2017 |
Key People
Founding team and executive leadership
ImmunoMet Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| InterVest | Series B |
| SL Investment | Series B |
| NHN Investment | Series B |
| Mirae Asset Venture Investments | Series B, Series A |
| Mirae Asset Venture Investment | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors grew 78% MoM.
- May 17, 2026
Monthly visitors grew 32% MoM, reaching 1.3K.
ImmunoMet Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about ImmunoMet Therapeutics's valuation, stock price, and market status.
Is ImmunoMet Therapeutics a public or private company?
ImmunoMet Therapeutics is a private company.
What is the current stock price of ImmunoMet Therapeutics?
ImmunoMet Therapeutics is a private company, so its shares have no public market price. Caplight tracks ImmunoMet Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ImmunoMet Therapeutics worth (valuation)?
Valuation information for ImmunoMet Therapeutics is not publicly available.
Can I buy ImmunoMet Therapeutics stock?
ImmunoMet Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ImmunoMet Therapeutics's last funding round?
ImmunoMet Therapeutics's most recent funding round was Series C on October 19, 2022.
Who are the main investors in ImmunoMet Therapeutics?
Key investors in ImmunoMet Therapeutics include Mirae Asset Venture Investments, Mirae Asset Venture Investment.
Will ImmunoMet Therapeutics IPO soon?
No public IPO plans have been announced for ImmunoMet Therapeutics.
How can I track ImmunoMet Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in ImmunoMet Therapeutics's shares on secondary markets.